Nanobiotix Reports Encouraging Early Results from Phase 1 Study in NSCLC
Nanobiotix provided an update on its operational progress and financial results for the first half of 2026. The company's JNJ-1900 (NBTXR3) clinical development program produced encouraging data across multiple indications, including a Phase 1 study evaluating the treatment in patients with inoperable, locoregionally recurrent non-small cell lung cancer.
The study reported promising early results, with a one-year locoregional control rate of 79% and a one-year overall survival rate of 70%. The investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.
Nanobiotix also announced the completion of an oversubscribed €86 million global follow-on offering in May 2026, which extended its cash runway into 2029. The company's financial position has been strengthened through this transaction, and it now holds €110.9 million in cash and cash equivalents as of June 30, 2026.